Pricing Log in Create free account
Saturday 17 October 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Health Information Services

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024. In the quarter to June 2026, revenue fell 12.7%, EPS fell 150.0% and free cash flow fell 4.61%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

69.86 2.53 −3.49%
Market cap
$9.4B
P/E
0.0×
Fwd P/E
−38.1×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 16.88
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 3 — — 4 2 1 3 2 — 7 4 —
Insider Ownership 10.64%

Capital & Financial Ratios $m

Market Cap 9,430.00
Revenue 616.91
Net Income (75.12)
Free Cash Flow 121.44
Net Debt (552.03)
Current Ratio 5.69 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (38.10) (negative: loss-making)
P/S ratio 14.72 (above 10: high)
P/B ratio 11.00 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (110.96%) (below 0%: weak)
Next Y EPS Growth 5.28%
Next Y revenue growth (3.47%) (below 0%: weak)
Next 5Y EPS Growth (5.69%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 13.9×, against a ten-year median of 9.5×; over the ten years it ranged from 1.0× in 2025 to 62.8× in 2021.
P/S against its own 10 years 65.05%
10-year low 10-year high
P/B against its own 10 years 66.92%
10-year low 10-year high
EV/Sales against its own 10 years 65.11%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 389 393 523 552
Receivables 115 88 82 51
Inventory 74 83 56 53
Other — — — —
596 584 684 675
2023 2024 2025 Q'26
Payables 16 13 13 21
ST’ Debt — — — —
Other — — 23 7
127 118 153 119

Compound Annual Growth %

10y 5y 3y
Sales — 16.55% 7.57%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 1.50% (0.39%)

Revenue $m

Mar Jun Sep Dec Year
’26 151 151 — — —
’25 155 173 149 166 643
’24 141 153 152 165 611
’23 134 147 154 184 619
’22 114 115 131 156 516
’21 106 116 125 144 490
’20 72 43 72 112 299
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 26 17 — — —
’25 34 18 43 41 136
’24 (16) 7 22 (7) 7
’23 (4) (12) (25) 26 (15)
’22 (21) (17) (10) 14 (34)
’21 (4) 3 (26) 6 (21)
’20 (3) (30) (56) (130) (218)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 25 15 — — —
’25 32 16 43 39 130
’24 (19) 4 18 (9) (7)
’23 (9) (37) (41) 22 (65)
’22 (49) (44) (46) (26) (165)
’21 (43) (11) (46) (22) (123)
’20 (11) (36) (57) (152) (256)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.14) — — —
’25 (0.28) 0.28 (0.22) (0.13) (0.35)
’24 (0.50) (0.32) (0.30) (0.40) (1.52)
’23 (0.44) (0.53) (0.79) (0.41) (2.18)
’22 (0.38) (0.57) (0.37) (0.15) (1.46)
’21 (0.11) (0.10) (0.15) (0.16) (0.53)
’20 (0.22) (0.41) (0.65) (3.87) (5.37)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 45.11 48.78 128.15 23.81 33.79 12.95 6.78

Analyst estimates 2026–2028

Powerpack
High — — — 88.98 166.31 208.99 150.00 63.57 55.96 20.34
People
People Employees — — 401 200 290 417 453 451 410 473
Revenue/emp, $m — 0.00 0.36 1.23 1.03 1.18 1.14 1.37 1.49 1.36
Income, $m
Income, $m Revenue — 71 146 246 299 490 516 619 611 643
Gross margin, % — 85.14 80.41 75.18 80.44 84.89 76.69 66.15 67.86 69.05
EBT — (19) (112) (31) (534) (54) (162) (249) (178) (40)
EBT margin, % — (26.36) (76.82) (12.62) (178.85) (10.95) (31.36) (40.21) (29.09) (6.21)
Net income — (19) (112) (31) (543) (58) (166) (255) (183) (44)
Depreciation — 4 4 7 19 28 33 44 44 44
Per share, $
Per share, $ Revenue — 6.13 10.93 6.29 2.95 4.44 4.54 5.28 5.07 5.15
Earnings — (1.62) (8.40) (0.80) (5.37) (0.53) (1.46) (2.18) (1.52) (0.35)
Cash flow — (0.92) (5.71) 0.89 (2.15) (0.19) (0.30) (0.13) 0.06 1.09
Capex — (0.32) (0.50) (1.09) (0.38) (0.92) (1.16) (0.42) (0.11) (0.05)
Free cash flow — (1.25) (6.21) (0.21) (2.53) (1.11) (1.45) (0.55) (0.06) 1.04
Book value — 0.00 1.74 10.75 7.31 7.41 7.08 6.32 5.90 6.38
Shares, m — 12 13 39 101 110 114 117 120 125
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 0.00 0.00 29.78 47.93 33.51 7.79 10.28 2.83 3.17
P/B — 0.00 0.00 17.43 19.38 20.11 4.99 8.59 2.44 2.56
EV/Sales — 0.00 0.00 28.17 45.75 32.37 7.01 9.70 2.24 2.40
EV/FCF — 0.00 (7.40) (853.68) (53.71) (129.46) (21.90) (92.75) (203.00) 11.93
Cash, $m
Cash, $m Operating cash flow — (11) (76) 35 (218) (21) (34) (15) 7 136
Capex — (4) (7) (43) (38) (101) (132) (50) (13) (6)
Free cash flow — (14) (83) (8) (256) (123) (165) (65) (7) 130
Balance, $m
Balance, $m Working capital — 46 74 418 656 637 504 469 467 531
Total debt — 169 30 30 63 82 95 — — —
Net debt — 121 (35) (394) (680) (588) (433) (389) (393) (523)
Shareholders’ equity — — 23 420 739 818 806 741 710 796
Returns, %
Returns, % ROA — (18.76) (180.97) (8.56) (70.70) (5.98) (16.21) (25.59) (19.39) (4.44)
ROIC — (9.49) 0.00 (74.54) (566.77) (14.26) (28.13) (47.06) (38.39) (13.97)
ROE — 11.27 67.56 (31.24) (93.64) (7.48) (20.45) (32.98) (25.17) (5.78)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

10x Genomics vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TEM Tempus AI, Inc. $12.8B — (loss-making) — (loss-making) +21.56% (above 0%: growing) n/m −153.72% (below 0%: shrinking) 64.45% (19.85%) Compare
BTSG BrightSpring Health Services, Inc. $12.3B 34.0× 37.6× +23.05% (above 0%: growing) +192.86% (above 0%: growing) −39.62% (below 0%: shrinking) 12.72% 3.37% Compare
TXG 10x Genomics $9.4B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%)
HNGE Hinge Health Inc. $8.5B 73.5× 39.4× +53.00% (above 0%: growing) n/m +441.14% (above 0%: growing) 86.44% 19.00% Compare
HQY HealthEquity, Inc. $7.7B 33.0× 30.2× +7.64% (above 0%: growing) +14.49% (above 0%: growing) −3.44% (below 0%: shrinking) 73.55% 28.14% Compare
DOCS Doximity, Inc. $5.6B 34.8× 26.2× +7.34% (above 0%: growing) −53.57% (below 0%: shrinking) −34.14% (below 0%: shrinking) 84.87% 21.48% Compare
WAY Waystar Holding Corp. $5.4B 38.0× 22.4× +18.11% (above 0%: growing) +10.53% (above 0%: growing) −52.42% (below 0%: shrinking) 69.44% 23.79% Compare
HTFL Heartflow, Inc. $4.4B — (loss-making) — (loss-making) +47.57% (above 0%: growing) n/m +62.62% (above 0%: growing) 83.00% (27.93%) Compare
PRVA Privia Health Group, Inc. $2.9B 102× 87.8× +21.39% (above 0%: growing) +250.00% (above 0%: growing) −86.20% (below 0%: shrinking) 9.93% 1.86% Compare
Median of peers $6.6B 36.4× 33.9× +21.48% +14.49% −36.88% 71.50% 11.19%

All 51 Health Information Services stocks →

10x Genomics (TXG) key facts

  • Concern: 10x Genomics reported a net loss of $43.5 million, or a loss of $0.35 per share, for fiscal 2025.
  • Strength: 10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
  • 10x Genomics (TXG) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, TXG traded at $69.86, a market capitalization of $9.4 billion.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 14.7× sales.
  • Return on equity was −5.78% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 3.99 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

10x Genomics (TXG) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/TXG · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com